Biotech Values

[DewDiligence]

NVO has evidently gone into radio silence regarding the NDA for Victoza (liraglutide). NVO’s most recent public comment came in late October:

http://sec.gov/Archives/edgar/data/353278/000120864609000291/c101679.htm

Novo Nordisk continues the constructive dialogue with the United States Food and Drug Administration regarding the regulatory process for liraglutide. Formal feedback from the FDA regarding liraglutide, a once-daily human GLP-1 analogue, is still expected in the fourth quarter of 2009.

NVO submitted the Victoza NDA in May 2008; the original PDUFA date was in Mar 2009.